10-Q: Organovo Holdings Reports Progress on FXR314 IBD Treatment and 3D Tissue Models, Faces Nasdaq Minimum Bid Price Deficiency

Organovo Holdings, Inc., a clinical-stage biotechnology company, reported progress in its development of FXR314 for inflammatory bowel disease and its 3D tissue models, while also facing a Nasdaq minimum bid price deficiency notice.

Summary

• Organovo Holdings, Inc. is a clinical-stage biotechnology company focused on developing FXR314 for inflammatory bowel disease (IBD), including ulcerative colitis (UC).
• The company plans to initiate a Phase 2a clinical trial for FXR314 in UC in 2025.
• Organovo is also developing 3D tissue models to identify new drug targets and explore the mechanism of action of known drugs.
• The company formed the Mosaic Cell Sciences division in February 2024 to source primary human cells for research and development, and to sell to life science customers.
• Organovo received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.
• The company has until January 14, 2025, to regain compliance.
• For the six months ended September 30, 2024, Organovo reported total revenue of $0.1 million, a net loss of $5.9 million, and operating expenses of $6.1 million.
• As of September 30, 2024, the company had $3.2 million in cash and cash equivalents and an accumulated deficit of $345.6 million.
• Organovo's management has concluded that substantial doubt exists about the company's ability to continue as a going concern without additional funding.

Sentiment

Score: 3

Explanation: The document presents a mixed picture of Organovo's current state and future prospects. While the company is making progress in its drug development and 3D tissue model efforts, the Nasdaq delisting warning, substantial doubt about its ability to continue as a going concern, and the need for significant additional funding raise serious concerns about its financial stability and long-term viability.

Positives

• Organovo is making progress in developing FXR314, a promising drug candidate for IBD, with a Phase 2a clinical trial planned for 2025.
• The company's 3D tissue models have the potential to revolutionize drug discovery by providing more accurate and relevant disease models.
• The Mosaic Cell Sciences division could become a valuable source of revenue and reduce reliance on external cell suppliers.
• The company successfully raised $4.5 million in a public offering, providing some near-term funding.
• Organovo has reduced its operating expenses compared to the prior year period.

Negatives

• Organovo received a delisting warning from Nasdaq due to its stock price falling below the $1 minimum bid requirement.
• The company has a history of operating losses and expects to incur substantial additional losses in the future.
• Organovo's management has expressed substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company's accumulated deficit stands at $345.6 million as of September 30, 2024.
• Organovo faces intense competition in the biotechnology and pharmaceutical industry.
• The company's reliance on third-party suppliers for human cells could pose a risk to its operations.

Risks

• Organovo may be unable to regain compliance with Nasdaq's minimum bid price requirement, leading to delisting.
• The company may fail to secure the substantial additional funding needed to support future operations.
• Clinical trials for FXR314 may not be successful, or regulatory approval may not be obtained.
• The company's 3D tissue models may not be effective in identifying viable drug candidates.
• Mosaic Cell Sciences may not become a profitable commercial business.
• Organovo may face challenges in attracting and retaining key personnel.
• The company may be unable to adequately protect its intellectual property.
• Organovo may be subject to claims, litigation, and government investigations.
• Changes in healthcare legislation and reimbursement policies could adversely affect the company's future revenue.
• The ongoing conflict between Ukraine and Russia and the Israel-Hamas war may negatively impact the global economy and Organovo's business.

Future Outlook

Organovo plans to start a Phase 2a clinical trial for FXR314 in ulcerative colitis in calendar year 2025 and continue developing its 3D tissue models for drug discovery. The company expects its Mosaic Cell Sciences division to become a profit center that offsets overall R&D spending. Organovo anticipates total operating expenses for the fiscal year ending March 31, 2025, to be between $13.0 million and $15.0 million. The company acknowledges the need for substantial additional funding to support future operating activities and expresses going concern uncertainties.

Management Comments

• Our current clinical focus is in advancing FXR314 in IBD, including UC and Crohns disease (CD).
• We plan to start a Phase 2a clinical trial in UC in the calendar year 2025.
• We released Phase 2 data for FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH) in April 2024 that are supportive of ongoing development, and we believe FXR314 has a commercial opportunity in MASH, most likely in combination therapy.
• We are exploring the potential for combination therapies using FXR314 and currently approved mechanisms in preclinical animal studies and our IBD disease models.
• Our second focus is building high fidelity, 3D tissues that recapitulate key aspects of human disease.
• We use our proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease.
• We believe these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas.
• As with the clinical development program, we are initially focusing on the intestine and have ongoing 3D tissue development efforts in human tissue models of UC and CD.
• We use these models to identify new molecular targets responsible for driving the disease and to explore the mechanism of action of known drugs including FXR314 and related molecules.
• We intend to initiate drug discovery programs around these new validated targets to identify drug candidates for partnering and/or internal clinical development.
• In February 2024, we formed our Mosaic Cell Sciences division (Mosaic) to serve as a key source of certain of the primary human cells we utilize in our research and development efforts.
• We believe Mosaic can help us optimize our supply chain, reduce operating expenses related to cell sourcing and procurement and ensure that the cellular raw materials we use are of the highest quality and are derived from tissues that are ethically sourced in full compliance with state and federal guidelines.
• Mosaic provides us with qualified human cells for use in its clinical research and development programs.
• In addition to supplying us with primary human cells, Mosaic offers human cells for sale to life science customers, both directly and through distribution partners, which we expect to offset costs and over time become a profit center that offsets our overall R&D spending.

Industry Context

Organovo operates in the biotechnology industry, specifically in the areas of drug development and tissue engineering. The company's focus on developing FXR314 for IBD places it in competition with other companies developing treatments for inflammatory bowel diseases. Organovo's 3D tissue models are part of a growing trend in the industry to develop more accurate and predictive models for drug discovery and development, as an alternative to traditional animal models. The formation of Mosaic Cell Sciences reflects the increasing importance of reliable cell sourcing for research and development in the life sciences industry.

Comparison to Industry Standards

• Organovo's net loss of $5.9 million for the six months ended September 30, 2024, is not unusual for a clinical-stage biotechnology company. Many companies in this stage of development incur significant losses as they invest heavily in research and development. For example, other clinical-stage companies such as Viking Therapeutics (VKTX) and Madrigal Pharmaceuticals (MDGL) have reported net losses in recent quarters.
• Organovo's focus on developing 3D tissue models for drug discovery is in line with industry trends. Companies like Emulate, Inc. and MIMETAS are also developing organ-on-a-chip and 3D tissue models for drug testing and disease modeling. These models are considered more physiologically relevant than traditional 2D cell cultures and animal models.
• The company's strategy of establishing a division for cell sourcing, Mosaic Cell Sciences, is similar to approaches taken by other companies in the industry. For instance, Lonza Group, a major contract manufacturer, also offers cell sourcing and manufacturing services to the life sciences industry.
• Organovo's royalty revenue from its licensing agreement with BICO Group AB is comparable to other licensing deals in the biotechnology sector. Royalty rates for intellectual property licenses in the industry typically range from low single-digit to low double-digit percentages of net sales, depending on the technology and market.
• The company's efforts to reduce operating expenses are consistent with industry-wide cost management practices. Many biotechnology companies are focused on optimizing their spending to extend their cash runway and achieve financial sustainability.

Legal Proceedings

• On August 27, 2024, H.C. Wainwright & Co., LLC filed a complaint against Organovo in the State of New York, alleging a breach of a tail financing provision in an engagement agreement.
• Organovo is seeking compensatory and consequential damages and attorneys' fees.
• On October 18, 2024, Organovo filed an answer to the complaint and is defending the claims vigorously.
• The company recorded an accrual of $0.6 million for the loss contingencies associated with the H.C. Wainwright complaint during the three months ended September 30, 2024.

Related Party Transactions

• Organovo has an intercompany agreement with Viscient Biosciences, for which Keith Murphy, Organovo's Executive Chairman, serves as CEO and President.
• The agreement involves sharing certain facilities and equipment, and providing services related to 3D bioprinting technology.
• For the three months ended September 30, 2024, Organovo incurred $70,000 of toxicity testing services from Viscient.
• For the three months ended September 30, 2024, Organovo provided approximately $4,000 of histology services to Viscient.

Stakeholder Impact

• Shareholders: Potential delisting from Nasdaq could negatively impact stock liquidity and price. The need for additional funding may lead to further dilution.
• Employees: Uncertainty about the company's ability to continue as a going concern may raise concerns about job security.
• Customers: The success of Mosaic Cell Sciences could provide customers with a reliable source of high-quality human cells.
• Suppliers: Organovo's financial challenges may impact its ability to meet its obligations to suppliers.
• Creditors: The company's going concern uncertainties and need for additional funding may increase the risk for creditors.

Next Steps

• Organovo plans to initiate a Phase 2a clinical trial for FXR314 in ulcerative colitis in calendar year 2025.
• The company will continue developing its 3D tissue models for drug discovery, focusing initially on UC and CD.
• Organovo aims to establish its Mosaic Cell Sciences division as a profit center.
• The company needs to regain compliance with Nasdaq's minimum bid price requirement by January 14, 2025.
• Organovo will seek substantial additional funding to support future operating activities.

Key Dates

Keywords

Organovo, FXR314, inflammatory bowel disease, IBD, ulcerative colitis, UC, Crohn's disease, CD, 3D tissue models, drug discovery, biotechnology, clinical trial, Nasdaq, delisting, Mosaic Cell Sciences, primary human cells, financial results, going concern